• Users Online: 406
  • Print this page
  • Email this page
Year : 2012  |  Volume : 5  |  Issue : 2  |  Page : 189-190

Additional and prolonged anticoagulation in patients with acute coronary syndrome? The ATLAS ACS 2-TIMI 51 trial

Professor of Cardiology, Vienna Medical School, Vienna, Austria

Correspondence Address:
Alexander Niessner
Professor of Cardiology, Vienna Medical School, Vienna
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7707/hmj.v5i2.172

Rights and Permissions

The additional application of low-dose rivaroxaban twice daily to standard therapy showed improved efficacy in patients with acute coronary syndrome (ACS) in the ATLAS ACS 2-TIMI 51 (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction) study. All-cause mortality was even reduced with 2×2.5 mg rivaroxaban. However, increased efficacy was associated with worse safety with, most importantly, an increased rate of intracranial bleeding.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal